急性髓系白血病患者TET2单核苷酸多态性I1762V的临床意义及预后影响分析
研究采用高通量测序对413例急性髓系白血病患者骨髓样本中58种血液肿瘤相关基因进行靶向测序,分析TET2单核苷酸多态性位点I1762V的检出情况及其与临床特征、体细胞突变和预后的相关性。结果显示154例患者检出I1762V,携带者总生存率和无进展生存率显著高于野生型患者。
要点
- 413例急性髓系白血病患者中154例检出TET2单核苷酸多态性位点I1762V,检出比例为37.3%。
- 携带I1762V的患者总生存率、无进展生存率显著高于野生型患者(HR=0.57,P=0.030;HR=0.55,P=0.020)。
- DNMT3A突变的急性髓系白血病患者总生存率、无进展生存率低于野生型患者(HR=1.79,P=0.030;HR=1.74,P=0.040)。
核心结论
- TET2单核苷酸多态性位点I1762V可能与急性髓系白血病相关,是影响患者预后的有利因素。
- TET2单核苷酸多态性位点I1762V是急性髓系白血病患者的预后因素,可用于指导治疗和预后评估。
研究设计与样本
- 采用高通量测序方法,对2016年7月至2019年12月于河南省肿瘤医院血液科就诊的413例急性髓系白血病患者骨髓样本中的58种血液肿瘤相关基因进行靶向测序。
- 统计TET2单核苷酸多态性位点I1762V的检出情况,并分析其与患者临床特征、体细胞突变及预后的相关性。
主要发现
- 154例急性髓系白血病患者检出TET2单核苷酸多态性位点I1762V,检出比例为37.3%,与NyuWa中国人群变异数据库对照人群相比差异有统计学意义(χ²=72.4,P<0.001)。
- TET2单核苷酸多态性位点I1762V与急性髓系白血病患者的性别、年龄、染色体核型均无明显相关性(P值均>0.05)。
- 携带TET2单核苷酸多态性位点I1762V的患者伴发NPM1基因突变和KIT基因突变的比例显著高于非携带者(P<0.001),且NPM1和KIT突变互斥发生。
- 携带TET2单核苷酸多态性位点I1762V的急性髓系白血病患者总生存率、无进展生存率显著高于野生型患者(HR=0.57,P=0.030;HR=0.55,P=0.020)。
- 不论是否携带TET2单核苷酸多态性位点I1762V,DNMT3A突变的急性髓系白血病患者总生存率、无进展生存率均低于野生型患者(HR=1.79,P=0.030;HR=1.74,P=0.040)。
临床怎么用
- 作者认为TET2单核苷酸多态性位点I1762V可用于指导急性髓系白血病的治疗和预后评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aimed to investigate the clinical and prognostic significance of TET2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia (AML) . Methods: The high-throughput sequencing method was used to sequence 58 hematological tumor-related genes in bone marrow samples from 413 patients with AML. TET2 I1762V and other somatic mutations were annotated and compared with patients' clinical information and prognosis. Results: I1762V was found in 154 patients with AML, which was significantly different from the general population in NyuWa Chinese Population Variant Database (χ(2)=72.4, P<0.001) . I1762V was not related to sex, age, and karyotype of patients with AML (P>0.05) . Patients with I1762V had a significantly higher proportion of NPM1 and KIT gene mutations than others (P<0.001) . NPM1 and KIT mutations were mutually exclusive. The survival analysis results revealed that the overall survival (OS) and progression-free survival (PFS) of patients with AML with I1762V were significantly greater than those of wild-type patients (HR=0.57, P=0.030; HR=0.55, P=0.020) , whereas the OS and PFS in patients with AML with DNMT3A mutation (with or without I1762V mutation) were lower than those of wild-type patients (HR=1.79, P=0.030; HR=1.74, P=0.040) . Conclusion: TET2 SNP I1762V has been linked to AML. I1762V is a prognostic factor of patients with AML, which can be used to guide the treatment and evaluate the prognosis of AML. 目的: 探讨TET2单核苷酸多态性(SNP)位点I1762V在急性髓系白血病(AML)患者中的临床意义及其对预后的影响。 方法: 采用高通量测序方法,对2016年7月至2019年12月于河南省肿瘤医院血液科就诊的413例AML患者骨髓样本中的58种血液肿瘤相关基因进行靶向测序。统计TET2 SNP位点I1762V的检出情况,并分析其与患者的临床特征、体细胞突变、预后的相关性。 结果: 154例AML患者检出TET2 SNP位点I1762V,检出比例为37.3%,与公共数据库(NyuWa Chinese Population Variant Database,NCVD)对照人群相比差异有统计学意义(χ(2)=72.4,P<0.001);TET2 SNP位点I1762V与AML患者的性别、年龄、染色体核型等均无明显相关性(P值均>0.05)。携带TET2 SNP位点I1762V的患者伴发NPM1基因突变和KIT基因突变的比例显著高于非携带者(P<0.001),且NPM1和KIT突变互斥发生。生存分析结果显示,携带TET2 SNP位点I1762V的AML患者总生存(OS)率、无进展生存(PFS)率显著高于野生型患者(HR=0.57,P=0.030;HR=0.55,P=0.020);不论是否携带TET2 SNP位点I1762V,DNMT3A突变的AML患者OS率、PFS率均低于野生型患者(HR=1.79,P=0.030;HR=1.74,P=0.040)。 结论: TET2 SNP位点I1762V可能与AML相关,可用于指导治疗和预后评估。TET2 SNP位点I1762V是影响AML患者预后的有利因素。.
引用
- Li YW, Guo Z, Wang LL, et al. [Analysis of clinical significance and prognostic impact of TET2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35405783. doi:10.3760/cma.j.issn.0253-2727.2022.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。